Leadership – DYSIS Medical


DYSIS Medical is a forward-looking medical technology company that combines innovative computer-aided cervical mapping technology with advanced colposcope design to help healthcare professionals detect cervical lesions efficiently and direct the patient journey with greater assurance.

    Board of Directors

    John Pedersen

    Mr. Pedersen joined DYSIS Medical as Chairman of the Board in December 2019.  Prior to joining the Board of Directors, Mr. Pedersen was CEO at Augmenix, Inc., which in was acquired by Boston Scientific Corp. in late 2018.  Previous to Augmenix, he was a Senior Healthcare Advisor for two Healthcare Private Equity Funds – The Gores Group and The Pritzker Group. Prior to this, Mr. Pedersen was President of the Urology and Women’s Health Division at Boston Scientific. During his 15 years at Boston Scientific, he also served as President of the Peripheral Interventions and the Neurovascular Divisions. Prior to Boston Scientific, he was a Senior Engagement Manager at McKinsey & Co.  Mr. Pedersen earned an MBA from The Harvard Graduate School of Business Administration and an AB degree from Princeton University.

    Mette Kirstine Agger

    Ms. Agger serves on numerous boards of both private and public companies, including KLIFO, a pharmaceutical consulting company, Lexeo, a gene therapy company targeting orphan diseases, DYSIS Medical, a womens health medtech company, and Psioxus, a tumor re-engineering company, ScPharmaceuticals, focused on novel solutions for out-patient care, and C.V Obel A/S, an investment company Ms. Agger has served 12 years from Sept 2009 to April 2022 as a managing partner of Lundbeckfonden Ventures, a life science venture fund, and as part of the management at Lundbeckfonden. Prior to that, Ms. Agger co-founded 7TM Pharma A/S, a biotech company engaged in therapeutic drug discovery and development, in 2000, and served as its chief executive officer from founding to 2009. Prior to founding 7TM Pharma, Ms. Agger was part of the management team of NeuroSearch A/S, a former drug research and development company. Ms. Agger graduated with an M.Sc. in Biology from the University of Copenhagen and has an M.B.A. from Henley Business School University of Reading. We believe Ms. Agger is qualified to serve on our board of directors because of her industry experience, intellectual property knowledge and her experience of serving on the boards.

    Jacob Falck Hansen

    Mr. Hansen is a Partner at Lundbeckfonden BioCapital. Prior to that, he worked at Novo Nordisk A/S for 15 years, most recently as Head of Corporate Strategy supporting its Executive Management and Board of Directors. Mr. Hansen has a deep understanding of the pharma industry across all parts of the value chain and many disease areas. He has significant experience with strategy development and execution and has been a trusted advisor to senior leadership in Novo Nordisk. Mr. Hansen holds an MSc in Biochemistry and a PhD from the University of Copenhagen. He is the author of more than 25 peer-reviewed scientific publications, including several in high-ranking journals such as Nature and Science, and the recipient of three prestigious awards for young researchers, including the Lundbeck Foundation Talent Prize.

    Ken Reali

    Mr. Reali is currently the CEO of Bioventus after being appointed to the role in April of 2020. Prior to that, Mr. Reali served as President and CEO of Clinical Innovations, a medical device company focused in woman’s healthcare, from June 2015 until its successful sale to Laborie in early  2020. During his twenty-nine-year medical device career, Mr. Reali has gained significant experience in product development, global marketing, business development, commercialization and sales of medical devices. He has a strong background in ethics and compliance, market analysis, reimbursement strategy, regulatory and clinical affairs, new product development, sales force optimization and domestic and international product commercialization.

    Darin Hammers

    Mr. Hammers is President and Chief Executive Officer of EndoGastric Solutions, Inc. Previously, he served as Chief Executive Officer of DYSIS Medical from September 2018 to December 2022. Mr. Hammers’ experience includes over 30 years of increasing leadership roles in the medical device industry. Prior to joining DYSIS, he served as the President and CEO of Cogentix Medical which was acquired by Laborie in April of 2018.  He joined Cogentix’s predecessor company Uroplasty as Vice President of Global Sales in January 2013 and was promoted to Chief Operating Officer prior to being named interim President and CEO in May 2016, and President and CEO in July 2016. Prior to joining Uroplasty, Mr. Hammers was Vice President of Sales for Bard Medical Division of C.R. Bard based in Covington, GA, focused on Urology care products. Prior to that, Mr. Hammers spent more than 12 years with Boston Scientific in various sales leadership positions in the Urology/Gynecology areas.

    Leadership Team

    David Inman

    CFO / Interim CEO

    David Inman joined the DYSIS Medical team in March 2020.  Prior to DYSIS, Mr. Inman was the VP of Finance and Accounting at Augmenix, Inc., which was sold to Boston Scientific at the end of 2018. Mr. Inman stayed at Boston Scientific until early 2020 as VP of Finance to help guide the successful transition and integration of the acquisition.  Prior to Augmenix, Mr. Inman was with Haemonetics Corporation as head of Global Financial Planning & Analysis, and previously had held Finance, Marketing, New Business Development, and Strategic Planning roles at Boston Scientific Corporation and Staples, Inc. Mr. Inman earned a BA in Economics from the University of Pennsylvania, and an MBA in Finance and Strategic Management from The Wharton School at the University of Pennsylvania.

    Chris Arnold

    Chief Commercial Officer

    Chris joined DYSIS in July 2022 with over 25 years of experience in the medical device industry, including over 16 years of leading sales managers and over nine years of executive leadership roles. Chris started his medical device career at Boston Scientific, taking on ever-increasing roles on the commercial team, including co-directing the rapid growth Women’s Health Division that grew from $35M to $105M in four years. In addition, he had successful leadership roles at both Smith and Nephew Orthopedics and Greatbatch Medical, leading to record growth and revenue at both organizations. Prior to DYSIS, Chris’ most recent two roles were as Vice President of Sales at Cogentix Medical and Z-Medica, both early commercial-stage high growth potential companies. In these roles, Chris worked with his team to develop a focused strategy and sales process, created a culture of entrepreneurial team contribution, and scaled both organizations for consistent growth and success.

    Carlos Morales

    Vice President Research & Development

    Carlos joined DYSIS Medical in April 2022 with almost 30 years of experience in product development, focusing on medical devices since 2001. As an expert in computer vision, image processing, and software, he has led the design and development of industrial and medical imaging systems, supervising engineering teams spanning the disciplines of electrical, mechanical, optical, wireless connectivity, and software engineering, including embedded, desktop, mobile, and cloud-based software. Most recently, Carlos was Senior Director, Surgical Visualization and Software at Smith & Nephew, where he led a large R&D team distributed across North America, Europe, and Asia. His group developed capital equipment for use in minimally invasive arthroscopic surgery, designing Ultra-High Definition cameras, digital image processing units, and artificial intelligence algorithms that support orthopedic surgeons. Previously, he held multiple leadership roles at BD, Johnson and Johnson, Boston Scientific, and other companies. Carlos was also a successful entrepreneur, founding and leading Axon Electro-Photonics, a manufacturer of computer vision systems for applications in the semiconductor industry.